A Comparison of Calcium to Zoledronic Acid for Improvement of Cortical Bone in an Animal Model of CKD
Open Access
- 3 September 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 29 (4) , 902-910
Abstract
: Patients with chronic kidney disease (CKD) have increased risk of fractures, yet the optimal treatment is unknown. In secondary analyses of large randomized trials, bisphosphonates have been shown to improve bone mineral density and reduce fractures. However, bisphosphonates are currently not recommended in patients with advanced kidney disease due to concern about oversuppressing bone remodeling, which may increase the risk of developing arterial calcification. In the present study we used a naturally occurring rat model of CKD with secondary hyperparathyroidism, the Cy/+ rat, and compared the efficacy of treatment with zoledronic acid, calcium given in water to simulate a phosphate binder, and the combination of calcium and zoledronic acid. Animals were treated beginning at 25 weeks of age (approximately 30% of normal renal function) and followed for 10 weeks. The results demonstrate that both zoledronic acid and calcium improved bone volume by micro–computed tomography (µCT) and both equally suppressed the mineral apposition rate, bone formation rate, and mineralizing surface of trabecular bone. In contrast, only calcium treatment with or without zoledronic acid improved cortical porosity and cortical biomechanical properties (ultimate load and stiffness) and lowered parathyroid hormone (PTH). However, only calcium treatment led to the adverse effects of increased arterial calcification and fibroblast growth factor 23 (FGF23). These results suggest zoledronic acid may improve trabecular bone volume in CKD in the presence of secondary hyperparathyroidism, but does not benefit extraskeletal calcification or cortical biomechanical properties. Calcium effectively reduces PTH and benefits both cortical and trabecular bone yet increases the degree of extra skeletal calcification. © 2014 American Society for Bone and Mineral Research.Keywords
This publication has 45 references indexed in Scilit:
- Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing DialysisNew England Journal of Medicine, 2012
- FGF23 induces left ventricular hypertrophyJournal of Clinical Investigation, 2011
- The pathophysiology of early-stage chronic kidney disease–mineral bone disorder (CKD-MBD) and response to phosphate binders in the ratJournal of Bone and Mineral Research, 2011
- Discriminants of Prevalent Fractures in Chronic Kidney DiseaseJournal of the American Society of Nephrology, 2011
- Bone Mass and Microarchitecture in CKD Patients with FractureJournal of the American Society of Nephrology, 2010
- Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failureKidney International, 2009
- A Structural Approach to Skeletal Fragility in Chronic Kidney DiseaseSeminars in Nephrology, 2009
- A rat model of chronic kidney disease-mineral bone disorderKidney International, 2009
- Chronic kidney disease and bone fracture: a growing concernKidney International, 2008
- Prolonged Efficacy of a Single Dose of the Bisphosphonate Zoledronic AcidClinical Cancer Research, 2007